Clinical Recommendations for the Perioperative Management of Biologic Medications for Nonrheumatologic Diseases in Total Joint Arthroplasty.

» Managing biologic therapies in nonrheumatologic patients undergoing total joint arthroplasty (TJA) poses unique risks, such as infection, and wound healing issues, yet guidelines are limited.» Some agents may be continued during the perioperative period, while others may need to be temporarily withheld before surgery.» The absence of clear perioperative guidelines for patients on biologics underscores the need for evidence-based protocols to support optimal surgical outcomes.» A deeper understanding of biologic pharmacodynamics in the perioperative period can help manage risks, particularly as the demand for TJAs in biologic-treated patients grows.